Roivant Sciences’ rare disease offshoot, Enzyvant, is partnering up with PerkinElmer Genomics to develop a test for the genetic mutations associated with Farber disease, an ultrarare lysosomal storage ...
RESEARCH TRIANGLE PARK, N.C. & BASEL, Switzerland--(BUSINESS WIRE)--Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and ultra-rare diseases, ...
SAN ANTONIO — A San Antonio family is in a race against time to find a cure for their 15-month-old son, Zayd, who is battling an extremely rare and terminal genetic disorder known as Farber disease.
Roivant Sciences Ltd, a biopharmaceutical company, and Plexcera Therapeutics LLC (Plexcera), engaged in developing rhAC therapy for Farber disease, have announced the formation of Enzyvant Sciences ...
Enzyvant announced that the Food and Drug Administration (FDA) has granted RVT-801 both Rare Pediatric Disease and Fast Track designations for Farber disease. Enzyvant announced that the Food and Drug ...
Editor’s note: Startup Spotlight is a regular part of WRAL TechWire’s Startup Monday package that includes our Jobs Report, Startup Guide updates, previews of local and North Carolina events, a recap ...
Editor’s note: Startup Spotlight is a regular part of WRAL TechWire’s Startup Monday package which includes our Triangle Startup Guide updates, our exclusive Triangle tech meetup list, multiple ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Here are today's five things you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback